相关实验视频

Updated: Jun 6, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

病例报告:阿布罗西提尼布:一种潜在的治疗选择,用于与皮肤炎相关的粉粉症

Yizhen Zhang^1,2, Dawei Huang^1,2, Yunlu Gao^1,2

¹School of Medicine, Tongji University, Shanghai, China.

Frontiers in immunology

|November 29, 2024

概括

在一项案例研究中,abrocitinib有效治疗了严重的亚托皮性皮肤炎 (AD) 的 Amyloidosis (LA). 治疗显著减少了皮肤病变和,显示出这种疾病有前途的治疗潜力.

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

Amyloidosis (LA) 是一种主要的皮肤 Amyloidosis,引起严重的.
目前对LA的治疗方法缺乏标准化,需要新的治疗方法.
亚努斯酶1抑制剂阿布罗西替尼 (abrocitinib) 已被批准用于治疗严重的阿托皮性皮炎 (AD) 和缓解.

研究的目的:

为了评估abrocitinib在患有 Amyloidosis和严重皮炎的患者中的疗效和安全性.
评估abrocitinib对这种结合条件下的皮肤病变严重程度和的影响.

主要方法:

一个病例报告,一名32岁的男性被诊断患有LA和严重AD.
由于传统疗法失败,开始使用abrocitinib治疗.
在治疗前和治疗后,对湿疹区域和严重性指数 (EASI) 评分和临床症状进行了监测.

主要成果:

患者的EASI评分在接受abrocitinib治疗的一个月内从48分显著下降到15分.
阿布罗西替尼导致的显着减少,皮肤病变厚度和色素的改善.
该疗法表现出卓越的疗效和良好的安全性.

结论:

阿布罗西替尼在治疗严重的亚托皮性皮肤炎和 Amyloidosis同时发生的治疗中显示出显著的治疗潜力.
需要进一步的临床研究来确认abrocitinib在LA和严重AD的益处.
阿布罗西提尼布为耐火性LA和AD患者提供了一个有前途的治疗选择.

关键词:

亚布罗西提尼布 (abrocitinib) 是一种药物.亚托邦性皮肤炎的发生.案例报告案例报告类 Amyloidosis 是一种类类类.小分子药物小分子药物

更多相关视频

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...